What is the treatment for croup using racemic epinephrine (adrenaline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Croup with Racemic Epinephrine

For moderate to severe croup, nebulized racemic epinephrine at a dose of 0.05 mL/kg of 2.25% solution (maximum 0.5 mL) in 2 mL of normal saline is recommended, with hospital admission considered only after three doses are required. 1, 2

Dosing and Administration

  • Standard dosing is 0.05 mL/kg of 2.25% racemic epinephrine (maximum 0.5 mL) in 2 mL normal saline administered by nebulizer 2
  • Many institutions use a standardized 0.5 mL dose for all patients regardless of weight 2
  • If racemic epinephrine is unavailable, L-epinephrine (1:1000) can be substituted at a dose of 0.5 mL/kg up to 5 mL 2, 3
  • Low-dose L-epinephrine (0.1 mg/kg) has been shown to be non-inferior to conventional dosing (0.5 mg/kg) with potentially fewer side effects 4

Treatment Algorithm Based on Severity

  • For mild croup: oral corticosteroids only, no nebulized treatments needed 1
  • For moderate to severe croup with stridor at rest or respiratory distress: nebulized racemic epinephrine plus oral corticosteroids 1, 5
  • All patients with croup requiring racemic epinephrine should receive at least a single dose of dexamethasone (0.6 mg/kg) 6, 7

Monitoring and Observation

  • Patients must be observed for at least 2-3 hours after the last dose of racemic epinephrine to monitor for symptom rebound 1, 2
  • The effect of racemic epinephrine is short-lived, lasting approximately 1-2 hours 8, 1
  • Clinical improvement is typically seen within 10-30 minutes after administration 9

Admission Criteria

  • Recent guidelines recommend considering hospital admission only after 3 doses of racemic epinephrine are required, rather than the traditional 2 doses 8, 2
  • This "3 is the new 2" approach has been shown to reduce hospital admissions by 37-57% without increasing adverse outcomes or revisits 8, 2
  • In one study, the admission rate among patients who received 2 or fewer racemic epinephrine doses was reduced by over 50% using this approach 8

Discharge Criteria

  • Patients can be safely discharged if they have:
    • No stridor at rest
    • Minimal or no respiratory distress
    • Adequate oral intake
    • Parents able to recognize worsening symptoms 1
  • Patients treated with racemic epinephrine, oral dexamethasone, and mist who show sustained response after 3 hours of observation can be safely discharged home 7

Important Cautions

  • Nebulized racemic epinephrine should not be used in children who are shortly to be discharged or on an outpatient basis due to risk of rebound symptoms 8, 5
  • Racemic epinephrine should never be used in the home setting due to its short duration of action and potential adverse effects 2
  • Potential adverse effects include increased heart rate, myocardial irritability, and increased oxygen demand 2

Common Pitfalls to Avoid

  • Discharging patients too early after nebulized epinephrine (before the 2-hour observation period) 1
  • Failing to administer corticosteroids in conjunction with racemic epinephrine 1, 6
  • Relying on radiographic studies for diagnosis rather than clinical assessment 5
  • Using only 1-2 doses of racemic epinephrine as the threshold for hospital admission, which may lead to unnecessary hospitalizations 8

References

Guideline

Treatment of Croup with Nebulization

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Racemic Epinephrine Administration and Clinical Applications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Croup in Toddlers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study.

American journal of diseases of children (1960), 1978

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.